Leerink Swann rated Buy Catalyst Biosciences Inc. (NASDAQ: CBIO) on 09/20/2007, when the stock price was $1.27. Since then, Catalyst Biosciences Inc. has lost 74.59% as of 08/28/2015's recent price of $0.32.
If you would have followed this Leerink Swann 's recommendation on CBIO, you would have lost 74.58% of your investment in 2899 days.

Targacept

Leerink Swann Equity Research provides unique perspectives and agenda-setting healthcare recommendations for investors. Supported by industry-based intelligence and thorough market examination, our proprietary research enables our clients to make well-informed healthcare investment decisions. Our investment perspectives are driven by proprietary insights from MEDACorp. MEDACorp's more than 25,000 network professionals work with new and/or development-stage pharmaceuticals, medical devices and biotherapeutics on a daily basis. MEDACorp's extensive knowledge of products and research enables Leerink Swann to provide growth-focused clients an expertise earned through experience.

Marked as spam